Crossmark

Response to “Unexpected mutations after CRISPR–Cas9 editing in vivo”

Crossref DOI link: https://doi.org/10.1038/nmeth.4541

Published Online: 2018-03-30

Published Print: 2018-04

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Lareau, Caleb A

Clement, Kendell http://orcid.org/0000-0003-3808-0811
Hsu, Jonathan Y

Pattanayak, Vikram

Joung, J Keith http://orcid.org/0000-0001-5630-5645
Aryee, Martin J http://orcid.org/0000-0002-6848-1344
Pinello, Luca
License Information

Text and Data Mining valid from 2018-03-30
More Information

Article History

First Online: 30 March 2018

Competing interests

: J.K.J. has financial interests in Beam Therapeutics, Editas Medicine, Monitor Biotechnologies, Pairwise Plants, Poseida Therapeutics, and Transposagen Biopharmaceuticals. M.J.A. has financial interests in Monitor Biotechnologies. J.K.J.'s and M.J.A.'s interests were reviewed and are managed by Massachusetts General Hospital and Partners HealthCare in accordance with their conflict of interest policies.